# A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.

Study · id `cardio:ct-nct04028518` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT04028518](<https://clinicaltrials.gov/study/NCT04028518>), retrieved 26 October 2026. No person wrote or checked this page.

Also called: NCT04028518

Browse, organ or system: Brain  
Browse, condition area: Stroke  

## In plain language

A phase 2 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 180 participants.

## Technical summary

Registry record NCT04028518. Randomized; no masking; primary purpose treatment. Start 2019-07-20 (anticipated); primary completion 2020-10-31 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; no masking; primary purpose treatment
- Phase: Phase 2
- Enrolled: 180 participants (planned count; ClinicalTrials.gov record NCT04028518, source copy `cardio:ctgov-nct04028518-2019-07-22`, retrieved 2026-10-26)
- Planned start: 2019-07-20 (anticipated) (ClinicalTrials.gov record NCT04028518, source copy `cardio:ctgov-nct04028518-2019-07-22`, retrieved 2026-10-26)
- Primary completion: 2020-10-31 (anticipated) (ClinicalTrials.gov record NCT04028518, source copy `cardio:ctgov-nct04028518-2019-07-22`, retrieved 2026-10-26)
- Completion: 2021-03-31 (anticipated) (ClinicalTrials.gov record NCT04028518, source copy `cardio:ctgov-nct04028518-2019-07-22`, retrieved 2026-10-26)
- Countries: China (ClinicalTrials.gov record NCT04028518, source copy `cardio:ctgov-nct04028518-2019-07-22`, retrieved 2026-10-26)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct04028518-2019-07-22`, retrieved 2026-10-26)

## The registry's words

- Brief title: A PhaseⅡ of Injection for Recombinant Human Tissue Plasminogen Kinase Derivative in Treatment of Acute Ischemic Stroke.
- Condition: Acute Ischemic Stroke
- Intervention (Drug): r-PA
- Intervention (Drug): r-PA
- Intervention (Drug): Alteplase for Injection
- Lead sponsor: Angde Biotech Pharmaceutical Co., Ltd.
- Lead sponsor class: INDUSTRY
- Collaborator: Beijing Tiantan Hospital
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Ischemic stroke (`cardio:ischemic-stroke`)
- Registry condition terms include this condition: Stroke (`core:stroke`)
- Registry lists this organization as a collaborator: Beijing Tiantan Hospital (`cardio:org-beijing-tiantan-hospital`)

### Other papers using this trial's data

- Registry lists this paper as a derived reference; the paper's PubMed record names this trial's registry number and no other, PubMed types it as a trial report dated on or after the primary completion, neither its types nor its title mark it as a protocol, a design, an observational study or work outside the trial's own data, and PubMed shows no retraction or expression of concern: Safety and Efficacy of Reteplase Versus Alteplase for Acute Ischemic Stroke: A Phase 2 Randomized Controlled Trial (`cardio:pubmed-38152962`)

Courtesy of the U.S. National Library of Medicine.

## Provenance

Content hash: 1757bc71efd5c3cc0155f33138890d713e8a9c0d732c3444fd0f7a2b6ddae4fc
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
